Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) features progressive cartilage loss with no effective therapies to slow degeneration. This study investigated sturgeon cartilage peptides (SCPs) for OA repair and identified key bioactive peptides and mechanisms. SCPs, prepared by trypsin hydrolysis, were evaluated in in vitro and in vivo OA models. SCPs markedly improved cartilage damage, reduced matrix degradation, and increased chondrocyte proliferation to 126% (p < 0.05). Multiomics and docking analyses revealed integrin αvβ3-mediated PI3K/Akt pathway activation as the key mechanism, and four bioactive peptides were screened; they promoted S/G2 cell-cycle progression, reducing IL-1β-induced apoptosis from 33% to 19–28% (p < 0.05), and restored COL2A1 and proteoglycan synthesis. Mechanistically, these effects occurred via binding to integrin αvβ3 and upregulation of integrin αV, integrin β3, PI3K, Akt, SOX9, and CCND1, and were attenuated by Cyclo(-RGDfK). Therefore, SCPs improve the OA phenotype by promoting synthesis and repair responses through the αvβ3–PI3K/Akt pathway, and GDR6 (GDFGER) is a lead peptide, providing insights for marine peptide-based OA treatment.
No takes yet. Share an insight, caveat, or question.
Jing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: